Evaluation of the influence of physiological anti-coagulant factor, inflammation, and aging on the various anti-coagulation therapies
Not Applicable
- Conditions
- Atrial fibrillation, paroxysmal supraventricular tachycardia, ventricular arrhythmias, and patients with cardiac Implantable electronic device (CIED)
- Registration Number
- JPRN-UMIN000019496
- Lead Sponsor
- iigata University Graduate School of Medical and Dental Sciences
- Brief Summary
In contrast to warfarin treatment, DOAC treatment preserves thrombin generation in response to vascular injury and maintains protein C, protein S, and factor VII levels, which could partly explain the lower risk of hemorrhagic complications and thromboembolic events in patients using these anticoagulants. Among DOACs, direct thrombin inhibitors and factor Xa inhibitors may act differently on the coagulation system and this could lead to distinct clinical outcomes.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
The patient without prior written consent, and the patient who receives urgent treatment.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Major bleeding complication, ischemic stroke, TIA, systemic embolism
- Secondary Outcome Measures
Name Time Method